Business Segments · Acquired in-process research and development
Business Segments — Acquired in-process research and development
Over 2 years (FY 2023 to FY 2025), Business Segments — Acquired in-process research and development shows a downward trend with a -100.0% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ2 2023
Last reportedQ1 2026
How to read this metric
An increase indicates active inorganic growth and investment in future drug pipelines, while a decrease suggests a focus on internal development or a pause in acquisition activity.
Detailed definition
This represents the value assigned to research and development projects acquired through business combinations that have...
Peer comparison
Common in biopharmaceutical firms that utilize an 'incubator' or 'hub-and-spoke' model to acquire early-stage assets.
Metric ID:
roiv_segment_reportable_segment_acquired_in_process_research_and_developmentHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $26.45M | $0.00 | $0.00 |
| YoY Change | — | -100.0% | — |
Range$0.00 – $26.45M
CAGR-100.0%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Roivant Sciences's business segments — acquired in-process research and development?
- Roivant Sciences (ROIV) reported business segments — acquired in-process research and development of $0.00 in Q1 2026.
- What is the long-term trend for Roivant Sciences's business segments — acquired in-process research and development?
- Over 2 years (2023 to 2025), Roivant Sciences's business segments — acquired in-process research and development has grown at a -100.0% compound annual growth rate (CAGR), from $26.45M to $0.00.
- What does business segments — acquired in-process research and development mean?
- The cost of purchasing unfinished research and development projects from other companies.